134 related articles for article (PubMed ID: 27461522)
1. Synergistic inhibition of characteristics of liver cancer stem-like cells with a combination of sorafenib and 8-bromo-7-methoxychrysin in SMMC-7721 cell line.
Zou H; Cao X; Xiao Q; Sheng X; Ren K; Quan M; Song Z; Li D; Zheng Y; Zeng W; Cao J; Peng Y
Oncol Rep; 2016 Sep; 36(3):1731-8. PubMed ID: 27461522
[TBL] [Abstract][Full Text] [Related]
2. 8-bromo-5-hydroxy-7-methoxychrysin targeting for inhibition of the properties of liver cancer stem cells by modulation of Twist signaling.
Ren KQ; Cao XZ; Liu ZH; Guo H; Quan MF; Liu F; Jiang L; Xiang HL; Deng XY; Cao JG
Int J Oncol; 2013 Nov; 43(5):1719-29. PubMed ID: 23970349
[TBL] [Abstract][Full Text] [Related]
3. 8-Bromo-7-methoxychrysin-blocked STAT3/Twist axis inhibits the stemness of cancer stem cell-like cell originated from SMMC-7721 cells.
Luo Y; Cui Y; Cao X; Li X; Chen A; Zhang J; Chen X; Cao J
Acta Biochim Biophys Sin (Shanghai); 2017 May; 49(5):458-464. PubMed ID: 28369327
[TBL] [Abstract][Full Text] [Related]
4. 8-bromo-7-methoxychrysin suppress stemness of SMMC-7721 cells induced by co-culture of liver cancer stem-like cells with hepatic stellate cells.
Wen Q; Xu C; Zhou J; Liu NM; Cui YH; Quan MF; Cao JG; Ren KQ
BMC Cancer; 2019 Mar; 19(1):224. PubMed ID: 30866863
[TBL] [Abstract][Full Text] [Related]
5. 8-bromo-7-methoxychrysin inhibits properties of liver cancer stem cells via downregulation of β-catenin.
Quan MF; Xiao LH; Liu ZH; Guo H; Ren KQ; Liu F; Cao JG; Deng XY
World J Gastroenterol; 2013; 19(43):7680-95. PubMed ID: 24431896
[TBL] [Abstract][Full Text] [Related]
6. Reversal of liver cancer-associated stellate cell-induced stem-like characteristics in SMMC-7721 cells by 8-bromo-7-methoxychrysin via inhibiting STAT3 activation.
Cui Y; Sun S; Ren K; Quan M; Song Z; Zou H; Li D; Cao J
Oncol Rep; 2016 May; 35(5):2952-62. PubMed ID: 26935885
[TBL] [Abstract][Full Text] [Related]
7. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
[TBL] [Abstract][Full Text] [Related]
9. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
Zhai B; Zhang X; Sun B; Cao L; Zhao L; Li J; Ge N; Chen L; Qian H; Yin Z
Tumour Biol; 2016 Jun; 37(6):8047-55. PubMed ID: 26711788
[TBL] [Abstract][Full Text] [Related]
10. 8-bromo-7-methoxychrysin Reversed M2 Polarization of Tumor-associated Macrophages Induced by Liver Cancer Stem-like Cells.
Sun S; Cui Y; Ren K; Quan M; Song Z; Zou H; Li D; Zheng Y; Cao J
Anticancer Agents Med Chem; 2017; 17(2):286-293. PubMed ID: 26845136
[TBL] [Abstract][Full Text] [Related]
11. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ
Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma.
Jiang X; Feng K; Zhang Y; Li Z; Zhou F; Dou H; Wang T
Oncotarget; 2015 May; 6(14):12340-56. PubMed ID: 25895026
[TBL] [Abstract][Full Text] [Related]
15. Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro.
Morisaki T; Umebayashi M; Kiyota A; Koya N; Tanaka H; Onishi H; Katano M
Anticancer Res; 2013 Apr; 33(4):1387-95. PubMed ID: 23564777
[TBL] [Abstract][Full Text] [Related]
16. Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells.
Liu J; Liu Y; Meng L; Ji B; Yang D
Int J Med Sci; 2017; 14(6):523-529. PubMed ID: 28638267
[No Abstract] [Full Text] [Related]
17. Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma.
Cheng Y; Luo R; Zheng H; Wang B; Liu Y; Liu D; Chen J; Xu W; Li A; Zhu Y
Oncotarget; 2017 Apr; 8(14):23265-23276. PubMed ID: 28423574
[TBL] [Abstract][Full Text] [Related]
18. A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma.
Hu B; Sun D; Sun C; Sun YF; Sun HX; Zhu QF; Yang XR; Gao YB; Tang WG; Fan J; Maitra A; Anders RA; Xu Y
Biochem Biophys Res Commun; 2015 Dec; 468(4):525-32. PubMed ID: 26482853
[TBL] [Abstract][Full Text] [Related]
19. Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells.
Zhang Y; Zhang B; Zhang A; Zhao Y; Zhao J; Liu J; Gao J; Fang D; Rao Z
Clinics (Sao Paulo); 2012 Sep; 67(9):1093-9. PubMed ID: 23018309
[TBL] [Abstract][Full Text] [Related]
20. Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT.
Mao J; Yang H; Cui T; Pan P; Kabir N; Chen D; Ma J; Chen X; Chen Y; Yang Y
Eur J Pharmacol; 2018 Aug; 832():39-49. PubMed ID: 29782854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
